Poultry Vaccines Market Size & Share Forecasts - Growth Trends & Industry Analysis (2025 - 2030)

Poultry Vaccines Market Analysis

The poultry vaccines market forecast projects its value at USD 2.29 billion in 2025, with an anticipation to grow to USD 3.56 billion by 2030, at a compound annual growth rate (CAGR) of 9.22% throughout the forecast period from 2025 to 2030.

Poultry farming plays a crucial role in the global food industry, serving as a major source of protein. However, the increasing number of diseases continually jeopardize poultry health, resulting in economic setbacks for farmers and affecting food security. To address this issue, the adoption of vaccines in the poultry sector has grown significantly. Throughout the years, the market for poultry vaccines has experienced considerable expansion, fuelled by several factors, including higher poultry production, increased disease prevention awareness, and vaccine technology improvements.

The significant prevalence of diseases in poultry necessitates vaccination to prevent these illnesses, fuelling poultry vaccines market growth. For instance, the data published by the European Centre for Disease Prevention and Control (ECDC) in March 2024, reported that outbreaks of highly pathogenic avian influenza (HPAI) A(H5) were reported in domestic birds (227 cases) and wild birds (414 cases) across 26 countries in Europe during December 2023 to March 2024. In addition, the same source reported that most reported HPAI outbreaks in poultry were primary occurrences, with 147 out of 179 outbreaks. Thus, the high number of poultry diseases is likely to fuel the demand for vaccination, further contributing to the market growth.

Furthermore, the rising initiatives by governments to prevent poultry diseases for food safety through vaccination are expected to drive significant market growth during the projected period. For instance, in October 2024, the United States, via the United States Agency for International Development (USAID), pledged USD 57.4 million, in collaboration with Congress, to enhance food security initiatives and promote innovative climate-smart agricultural solutions aimed at decreasing global hunger, poverty, and undernutrition. Significant investments in Innovation Labs include a collaboration between the University of Florida and the University of California, Davis, focusing on poultry disease through advancements in chicken breeding. Additionally, in August 2023, the Ethiopian government launched its national poultry development strategy to improve food and nutrition security in the country. Thus, such government initiatives are expected to drive the adoption of poultry vaccines, and contributing to market growth.

All above-mentioned factors, like the high prevalence of poultry diseases and increasing government initiatives, are likely to drive the demand for poultry vaccines, boosting the market growth.

Poultry Vaccines Market Trends and Insights

The Bronchitis Segment is Anticipated to Hold the Largest Poultry Vaccines Market Share in the Disease Segment

The bronchitis segment is projected to experience the highest growth rate, with a CAGR of 7.53%. The revenue forecast is anticipated to be USD 0.48 billion in 2024 and climb to USD 0.67 billion by 2029.

Avian infectious bronchitis is a viral disease caused by the avian influenza virus, leading to significant losses in poultry, globally. The virus spreads rapidly within flocks and results in respiratory issues. Common symptoms of the infection include conjunctivitis, nasal discharge, coughing, and difficulty in breathing.

The high prevalence of bronchitis infection drives the need for poultry vaccines, hence contributing to the market growth. For instance, an article published in Frontiers in Cell and Infection Microbiology in February 2024 mentioned that infectious bronchitis virus (IBV) genotype I (GI) is widespread globally, with sporadic cases reported across various continents. In contrast, genotype II (GII) was recognized as a European strain that spread throughout Europe and South America. Thus, the presence of IBV strains across different continents will likely raise the demand for vaccines, as per the above industry analysis.

As the demand for infectious bronchitis vaccines continues to grow within poultry, researchers are focused on creating new vaccines and enhancing the safety and effectiveness of existing ones against infectious bronchitis viruses. These efforts aim to expand the availability of innovative vaccines in the market, which is expected to contribute to significant growth and positive market outlook during the forecast period. For instance, in August 2024, researchers at Pirbright Institute, in partnership with New England Biolabs, Inc., created a novel method for investigating the infectious bronchitis virus (IBV), a highly contagious pathogen affecting poultry. The research group utilized a data-optimized golden gate assembly technique to enhance their reverse genetics approach to studying IBV more effectively. Additionally, in January 2024, researchers at the Pirbright Institute discovered a method to create new vaccines for avian bronchitis that can replicate in cell culture. The research team uncovered a way to systematically modify IBV by targeting the spike gene, which reduces its virulence and enables it to replicate in a Vero cell line, which is widely used in microbiology and approved for vaccine production. Thus, such efforts implemented by the researchers to develop novel vaccines are likely to fuel the bronchitis segment growth.

The Live Attenuated Vaccines Segment is Anticipated to Hold the Largest Share Within the Technology Segment of the Poultry Vaccines Market

By technology, the live attenuated vaccines segment is anticipated to dominate the market share and is forecasted to experience a CAGR of 8.65% from 2024 to 2029. Projected to reach a market value of around USD 0.98 billion in 2024, the figure is set to climb to an estimated USD 1.4 billion by 2029.

 Live vaccines consist of a weakened form of the living pathogen, rendering them incapable of causing disease. These vaccines elicit a response that mimics a natural infection but is less intense. Following the administration of a live attenuated vaccine, the immune system produces robust cellular and antibody responses that often provide long-lasting immunity against the pathogen and the disease it causes, typically requiring only one or two doses. Factors such as the rising incidence of infectious diseases in poultry, the increasing demand for live attenuated vaccines, and the growing number of vaccine introductions are anticipated to drive the segment growth of live attenuated vaccines.

The poultry vaccines market is segmented by disease and technology. By disease, the market is segmented into bronchitis, avian influenza, Newcastle disease, Marek’s disease, coccidiosis, egg drop syndrome, avian encephalomyelitis, and others. The other disease segment comprises bursal diseases, laryngotracheitis, and viral enteritis, among others. By technology, the market is segmented into recombinant vaccines, inactivated vaccines, live attenuated vaccines, and others. The other technology segments include sub-unit and DNA vaccines. The segmentation enables stakeholders in the poultry vaccine market, including manufacturers, distributors, and farmers, to focus on particular needs and adjust their strategies accordingly.

North America is Anticipated to Grow Significantly in the Market Throughout the Forecast Period

The North American poultry vaccines market forecast includes projections of a 8.93% compound annual growth rate (CAGR) from 2024 to 2029, with an estimated market size of USD 0.78 billion in 2024 and a projected rise to USD 1.1 billion by 2029. The region is projected to capture a substantial market share during the forecast period, driven by factors such as rising consumption of poultry products, heightened consumer awareness about food safety, and a growing occurrence of zoonotic diseases linked to poultry.

The increasing incidence of disease outbreaks in poultry has the potential to cause substantial economic losses, prompting the poultry industry to actively pursue strategies for preventing or managing diseases such as avian influenza, Newcastle disease, and others. Vaccination is essential for preventing these illnesses and reducing their overall impact.

For instance, the data released by the United States Department of Agriculture (USDA) in November 2024 reported that H5 detections occurred in 50 commercial poultry flocks and 38 backyard flocks, affecting a total of 25.61 million birds in the United States in 2024. Thus, it is likely that commercial poultry farms are the major end users because of their extensive operations and emphasis on productivity and disease prevention, hence driving the poultry vaccine market growth in the United States.

Moreover, the data released by the Government of Canada in April 2024 reported that Canada documented a total of 2,906 suspected and confirmed positive samples of highly pathogenic avian influenza (HPAI) in wild birds across all provinces and territories in 2024. This is expected to result in a higher demand for efficient poultry vaccines to help prevent the spread of avian influenza and safeguard poultry populations from the disease.

Increasing investments in research and development focused on poultry vaccines is fueling market innovation. Pharmaceutical companies, biotechnology companies, market leaders and research institutions are working together to create new vaccines, diagnostics, and therapeutic solutions to improve the prevention and management of poultry disease outbreaks. For instance, in April 2024, Merck Animal Health announced a partnership with Cambridge Technologies, a custom vaccine company based in Worthington, Minnesota, to distribute and promote its innovative autogenous poultry vaccines within the United States. Thus, such initiatives and partnerships among market players are likely to drive the North American market growth for poultry vaccines.

In North America, significant progress in vaccine development encompasses live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-based vaccines, and live-gene-deleted vaccines, which are anticipated to drive market growth throughout the forecast period.

By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The East Africa and Asia Pacific regions, particularly nations like China, Japan, and India, are experiencing notable poultry vaccine industry growth driven by factors such as the increasing incidence of poultry and zoonotic diseases, a heightened emphasis on food safety, and several market player initiatives implemented in these countries.